Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NYSE:OGEN NASDAQ:ORGS NYSE:TMBR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.84+1.9%$0.51$0.17▼$2.93$2.66M-0.07160,536 shs4,570 shsOGENOragenics$1.27+5.0%$1.24$1.01▼$18.90$5.24M0.82308,868 shs320,928 shsORGSOrgenesis$0.02-97.3%$0.65$0.00▼$6.28$115K3.196,732 shs1,450 shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%+11.56%+43.86%+281.22%-70.82%OGENOragenics0.00%+12.04%+5.22%-72.18%-92.38%ORGSOrgenesis0.00%+429.41%+3,990.91%-52.13%+89,999,900.00%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.84+1.9%$0.51$0.17▼$2.93$2.66M-0.07160,536 shs4,570 shsOGENOragenics$1.27+5.0%$1.24$1.01▼$18.90$5.24M0.82308,868 shs320,928 shsORGSOrgenesis$0.02-97.3%$0.65$0.00▼$6.28$115K3.196,732 shs1,450 shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%+11.56%+43.86%+281.22%-70.82%OGENOragenics0.00%+12.04%+5.22%-72.18%-92.38%ORGSOrgenesis0.00%+429.41%+3,990.91%-52.13%+89,999,900.00%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/ATMBRTimber Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/AORGSOrgenesis$662K6.52N/AN/A($6.58) per share-0.14TMBRTimber Pharmaceuticals$80K0.00N/AN/A$1.79 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.950.05∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)OGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)TMBRTimber Pharmaceuticals-$19.38MN/A0.00N/AN/AN/A-511.45%-180.93%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70OGENOragenicsN/A1.931.93ORGSOrgenesisN/A0.070.07TMBRTimber PharmaceuticalsN/A0.500.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%OGENOragenics18.71%ORGSOrgenesis22.56%TMBRTimber Pharmaceuticals3.62%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%OGENOragenics4.90%ORGSOrgenesis5.66%TMBRTimber Pharmaceuticals1.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableOGENOragenics54.13 million10.98 millionN/AORGSOrgenesis1504.80 million4.53 millionNo DataTMBRTimber Pharmaceuticals93.43 million3.38 millionNot OptionableTMBR, OGEN, ORGS, and ATXI HeadlinesRecent News About These CompaniesMSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sourcesJanuary 31, 2025 | nypost.comNTimber back in Dutch squad and twin brother also called upAugust 30, 2024 | reuters.comRare disease drug from LEO's Timber felled by failed studyAugust 25, 2024 | pharmaphorum.comPCan timber construction overcome its growing pains?May 13, 2024 | reuters.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingMarch 10, 2024 | businesswire.comTimber Pharmaceuticals Announces Official Name ChangeJanuary 28, 2024 | msn.comTimber Pharmaceuticals Inc (TMBRQ)January 13, 2024 | uk.investing.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)November 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comMVST, FBIO and VTVT among mid-day moversNovember 21, 2023 | seekingalpha.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 17, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerNovember 16, 2023 | msn.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceSeptember 18, 2023 | finance.yahoo.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 29, 2023 | 247wallst.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 28, 2023 | msn.comTimber Pharmaceuticals rockets as it agrees to a takeoverAugust 21, 2023 | thepharmaletter.comTTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | benzinga.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeTMBR, OGEN, ORGS, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.84 +0.02 (+1.89%) As of 02:33 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Oragenics NYSE:OGEN$1.27 +0.06 (+4.96%) Closing price 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.57%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Orgenesis NASDAQ:ORGS$0.02 -0.88 (-97.33%) As of 03:43 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Timber Pharmaceuticals NYSE:TMBRTimber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
